Ambrx Biopharma is a startup based in the United States, most recent round Acquired.
Ambrx Biopharma is a startup based in the United States. Ambrx Biopharma has been acquired.
Ambrx Biopharma is a clinical-stage biopharmaceutical company that uses an expanded genetic code platform to discover and develop antibody–drug conjugates (ADCs) and other engineered protein therapies for oncology and immune modulation. The company advanced clinical programs including ARX517 (PSMA-targeting) and ARX788 (HER2-targeting) and was acquired by Johnson & Johnson in March 2024.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.